Literature DB >> 8030759

Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma.

J Cai1, P S Gill, R Masood, P Chandrasoma, B Jung, R E Law, S F Radka.   

Abstract

Oncostatin-M is a cytokine produced by macrophages and activated T lymphocytes that has recently been shown to be a mitogen for AIDS-related Kaposi's sarcoma (KS)-derived spindle cells. The significance of oncostatin-M production in AIDS-related KS in vivo, however, remains unknown. In this study we wanted to determine whether oncostatin-M is expressed in vivo in patients with HIV-I-related KS, define the cell types that express this cytokine, and compared with the control tissues from HIV-I-negative individuals. A second objective of our study was to define the expression of oncostatin-M in AIDS-KS-derived spindle cell isolates cultured in vitro and to determine whether oncostatin-M is an autocrine growth factor for these KS cells. We have determined that oncostatin-M is not expressed in any of the several organs examined in control cases, whereas the tumor tissue obtained from the skin biopsies of HIV-I-infected cases with KS displayed oncostatin-M expression in the spindle cell components of the tumor, as well as the cells lining the vascular structures, smooth muscle cells lining the eccrine sweat glands, and the epidermal layers of the skin. Furthermore, uninvolved skin of patients with HIV-related KS express oncostatin-M in the cells lining normal vessels. The mRNA polymerase chain reaction analysis confirmed findings in the primary tissues and showed expression in all of the AIDS-KS-derived spindle cell isolates examined. We have also shown with the use of oncostatin-M-specific antisense oligodeoxynucleotides that KS cell proliferation is inhibited, which correlated with a more precipitous decline in the production of interleukin-6 by these cells. We conclude that oncostatin-M is only expressed in the skin and KS tumor of HIV-I-infected individuals. Furthermore, we provide evidence that oncostatin-M is an autocrine growth factor for KS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8030759      PMCID: PMC1887313     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  11 in total

1.  Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin.

Authors:  R Masood; S R Husain; A Rahman; P Gill
Journal:  AIDS Res Hum Retroviruses       Date:  1993-08       Impact factor: 2.205

2.  AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.

Authors:  S A Miles; A R Rezai; J F Salazar-González; M Vander Meyden; R H Stevens; D M Logan; R T Mitsuyasu; T Taga; T Hirano; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

3.  Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells.

Authors:  S Nakamura; S Z Salahuddin; P Biberfeld; B Ensoli; P D Markham; F Wong-Staal; R C Gallo
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

4.  Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M.

Authors:  B C Nair; A L DeVico; S Nakamura; T D Copeland; Y Chen; A Patel; T O'Neil; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1992-03-13       Impact factor: 47.728

5.  Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells.

Authors:  S A Miles; O Martínez-Maza; A Rezai; L Magpantay; T Kishimoto; S Nakamura; S F Radka; P S Linsley
Journal:  Science       Date:  1992-03-13       Impact factor: 47.728

6.  Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells.

Authors:  J M Zarling; M Shoyab; H Marquardt; M B Hanson; M N Lioubin; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Abrogation of the antiproliferative activity of oncostatin M by a monoclonal antibody.

Authors:  S F Radka; J R Naemura; M Shoyab
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

8.  Regulation of IL-6 expression by oncostatin M.

Authors:  T J Brown; J M Rowe; J W Liu; M Shoyab
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

9.  AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects.

Authors:  B Ensoli; S Nakamura; S Z Salahuddin; P Biberfeld; L Larsson; B Beaver; F Wong-Staal; R C Gallo
Journal:  Science       Date:  1989-01-13       Impact factor: 47.728

10.  Relationship of serum levels of oncostatin M to AIDS-related and classic Kaposi's sarcoma.

Authors:  A S Hamilton; S F Radka; L Bernstein; P S Gill; M Gonsalves; J R Naemura; R K Ross
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-04
View more
  22 in total

1.  Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules.

Authors:  V Modur; M J Feldhaus; A S Weyrich; D L Jicha; S M Prescott; G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.

Authors:  V Fiorelli; R Gendelman; F Samaniego; P D Markham; B Ensoli
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

3.  Thymidine phosphorylase expression in Kaposi sarcoma.

Authors:  M A Dada; C H Boshoff; M A Comley; H Turley; J W Schneider; R Chetty; K C Gatter
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

4.  Tousled-like kinases modulate reactivation of gammaherpesviruses from latency.

Authors:  Patrick J Dillon; Sean M Gregory; Kristen Tamburro; Marcia K Sanders; Gary L Johnson; Nancy Raab-Traub; Dirk P Dittmer; Blossom Damania
Journal:  Cell Host Microbe       Date:  2013-02-13       Impact factor: 21.023

5.  Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells.

Authors:  M Mercader; B Taddeo; J R Panella; B Chandran; B J Nickoloff; K E Foreman
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  Resonance assignments for Oncostatin M, a 24-kDa alpha-helical protein.

Authors:  R C Hoffman; F J Moy; V Price; J Richardson; D Kaubisch; E A Frieden; J D Krakover; B J Castner; J King; C J March; R Powers
Journal:  J Biomol NMR       Date:  1996-06       Impact factor: 2.835

7.  Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.

Authors:  F Samaniego; P D Markham; R Gendelman; Y Watanabe; V Kao; K Kowalski; J A Sonnabend; A Pintus; R C Gallo; B Ensoli
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

8.  Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells.

Authors:  R K Ganju; N Munshi; B C Nair; Z Y Liu; P Gill; J E Groopman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  KSHV-induced notch components render endothelial and mural cell characteristics and cell survival.

Authors:  Ren Liu; Xiuqing Li; Anil Tulpule; Yue Zhou; Jeffrey S Scehnet; Shaobing Zhang; Jong-Soo Lee; Preet M Chaudhary; Jae Jung; Parkash S Gill
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

10.  Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.

Authors:  R Sun; S F Lin; K Staskus; L Gradoville; E Grogan; A Haase; G Miller
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.